The ACC is pleased to announce the recipients of its 2026 Distinguished Awards. This year's honorees represent an exceptional group of individuals whose past and ongoing efforts have made meaningful ...

CVD Risk Estimator Plus Estimate 10‑ and 30‑year risks for total CVD, ASCVD, and heart failure, using the combined strength of the new AHA PREVENT™ equations, as well as the previous Pooled Cohort ...

It is a tremendous honor to serve as Chair of ACC's Women in Cardiology (WIC) Member Section Leadership Council. I am deeply grateful to the visionary leaders who have built this extraordinary ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...

Long-term treatment with beta-blockers may not lower the risk of death or myocardial infarction (MI) in patients with MI, a preserved left ventricular ejection fraction (LVEF) of ≥50% and coronary ...

A single subcutaneous injection of the investigational drug zilebesiran, when added to existing treatment with a standard antihypertensive medication, reduced systolic blood pressure (SBP) by between ...

In the ABYSS (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization) trial, interruption of ...

Strategies such as earning points or small amounts of money encouraged people at high risk for heart disease or stroke to increase their daily walking by about 10% and sustain the increase for a year, ...

The newest clinical guideline released by the ACC and the American Heart Association (AHA) provides new and updated recommendations for preventing and optimally managing atrial fibrillation (AFib).

The following are key points to remember from the 2024 AHA/ACC/multisociety guideline for the management of hypertrophic cardiomyopathy (HCM): ...

The following are key points to remember from a 2024 American College of Cardiology (ACC) expert consensus decision pathway (ECDP) on strategies and criteria for the diagnosis and management of ...